Loading...
•
Sep 30, 2024
Assertio Q3 2024 Earnings Report
Assertio's third quarter results reflected stable performance, driven by Rolvedon and economic returns from the commercial portfolio.
Key Takeaways
Assertio Holdings reported solid performance in Q3 2024, with Rolvedon establishing itself as the lead asset, contributing to a total net product sales of $28.7 million. The company is implementing new strategies for Sympazan and maximizing the value of Indocin while evaluating new growth opportunities.
Rolvedon net product sales were stable at $15.0 million.
Indocin net product sales decreased to $5.7 million due to generic competition.
Gross margin increased to 74% due to a decrease in inventory write-downs and completion of Rolvedon inventory step-up amortization.
Cash, cash equivalents and short-term investments were $88.6 million.
Assertio
Assertio
Forward Guidance
Assertio did not provide specific forward guidance in this earnings report.